Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533897 | 0.84 | CYP19A1 (0.38) | CYP19A1NCEH1CYP3A4TXNRD1PIN1 | |
| SCHEMBL3529003 | 0.84 | CYP19A1 (0.38) | CYP19A1NCEH1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL4837581 | 0.82 | CA2 (0.38) | CYP3A4ALDH1A1CA1CA2CA9 | |
| SCHEMBL27716513 | 0.81 | CYP19A1 (0.39) | CYP19A1NCEH1TSHRALDH1A1TXNRD1 | |
| SCHEMBL4635823 | 0.74 | ALDH1A1 (0.54) | TSHRALDH1A1CA1CA2CA9 | |
| SCHEMBL3530271 | 0.73 | CYP19A1 (0.38) | CYP19A1NCEH1CYP3A4PTGESHTR6 | |
| SCHEMBL3535704 | 0.72 | CYP19A1 (0.36) | CYP19A1CYP3A4ALDH1A1TXNRD1HTR6 | |
| SCHEMBL14015215 | 0.71 | CYP19A1 (0.34) | CYP19A1NCEH1CYP3A4ALDH1A1PTGES | |
| SCHEMBL4636117 | 0.70 | NPC1 (0.35) | TSHRALDH1A1TXNRD1 | |
| SCHEMBL3534805 | 0.69 | NPC1 (0.43) | ALDH1A1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429582-B2 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders | WYETH (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007120599-A2 | DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280894-A1 | DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR2C | CYP19A1 1086/4885NCEH1 805/4885TSHR 465/4885 |
| US-20070244105-A1 | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | CYP19A1 1086/4885NCEH1 805/4885TSHR 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.